Latest News

Cord Blood, the source of cellular immunotherapy
The cord blood, found inside the umbilical cord of newborn infants, contains rich concentration of hematopoietic stem cells (HSCs), which produces all blood components as well as mesenchymal stem cells (MSCs) which form cartilage, bone and muscle. Furthermore, the cord blood derived cells posess strong proliferative potential with power to boost immunolgocial functions.

IMMUNIQUE specializes in cellular immunotherapy development
IMMUNIQUE specializes in cutting-edge biopharmaceutical R&D utilizing immune cells from cord blood (regulatory-T cells and NK cells) to develop treatments for intractable diseases such as immunological disorders and cancer.

The Future of Cellular Immunotherapy
To find the blue ocean in the red ocean of cellular therapy, which finally would be the PURPLE ocean.

IMMUNIQUE’s R&D Center for Cellular Immunotherapy
The scientists and experts at IMMUNIQUE’s R&D Center will pave the way to find solutions for a wide range of intractable conditions for which no cure is currently available from autoimmune diseases and a variety of cancers.

Therapeutic Pipeline for Cellular Immunotherapy
IMMUNIQUE is developing cellular immunotherapy treatments for a wide range of intractable diseases ranging from autoimmune diseases to cancers.

IMQ-Treg-01 : Graft versus Host Disease80
IMQ-Treg-02 : Aplastic anemia40
IMQ-Treg-03 : Lupus20
IMQ-NK-01 : Solid tumor20

Would you like to learn more about IMMUNIQUE’s cellular immunotherapy?
Pleaes leave us an inquiry on IMMUNIQUE’s R&D progress and we will respond to you.